

18 March 2025

Advanced Medical Solutions Group plc
("AMS" or the "Group")

Directorate Change

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that Liz Shanahan has decided to step down as Chair and a Director of AMS for personal reasons. "It is with mixed emotions that I have made this decision, but circumstances mean I can no longer fulfil the responsibilities of Chair. It has been a pleasure working with AMS and, in particular, being Chair of the business through the transformational acquisition of Peters Surgical." said Liz Shanahan. In order to allow for an orderly handover, Liz will leave the Board with effect from 31 March 2025.

The Company is pleased to announce that Grahame Cook, Senior Independent Non-Executive Director, has been appointed as Non-Executive Chair with effect from 31 March 2025, retaining his positions on the Audit, Nominations and Remuneration Committee. Grahame was appointed to the Board in February 2021 has substantial global equity markets experience, having formerly worked as a managing director at UBS and joint Chief Executive of Panmure Gordon.

Grahame Cook said "On behalf of the Board, I would like to thank Liz for her contribution to the Group and wish her well for the future. I am honoured to succeed Liz as Chair of AMS, at an exciting moment for the business. I look forward to working with the Executive and the board to progress the Peters Surgical transaction which presents a compelling opportunity to accelerate the development of our business in the surgical sector."

Chris Meredith, CEO of AMS, commented "I would like to thank Liz for her guidance as our Chair for the last year and wish her well. I look forward to working closely with Grahame and the rest of the Board and drawing on their experience as we pursue the exciting opportunities ahead of us."

The Board is pleased to further announce that the search for an additional Non-executive Director is well advanced and a further announcement will be made in the near future.

- End -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Michael King, Investor Relations

Tel: +44 (0) 1606 545508

Investec Bank PLC (NOMAD & Broker)
Gary Clarence / David Anderson

Tel: +44 (0) 20 7597 5970

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,500 employees. For more information, please see www.admedsol.com.

-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAGPUUWWUPAPUM